AMRX Q2 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$725M+3.2% YoY

Gross Profit

$286M39.5% margin

Operating Income

$111M15.4% margin

Net Income

$22M3.1% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

$84M

Free Cash Flow

$57M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$3.5B

Stockholders' Equity

-$113M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$725M	$702M	+3.2%
Gross Profit	$286M	$250M	+14.5%
Operating Income	$111M	$95M	+16.7%
Net Income	$22M	$6M	+274.0%

Revenue Segments

Amneal Specialty Pharma Segment

$128M100%

Geographic Segments

Specialty Segment

$128M100%